Olina Efthymiadou1, Jean Mossman2, Panos Kanavos3. 1. Department of Health Policy, Medical Technology Research Group, London School of Economics, Houghton Street, WC2A 2AE, England, United Kingdom. Electronic address: a.efthymiadou@lse.ac.uk. 2. Department of Health Policy, Medical Technology Research Group, London School of Economics, Houghton Street, WC2A 2AE, England, United Kingdom. Electronic address: j.mossman@lse.ac.uk. 3. Department of Health Policy, Medical Technology Research Group, London School of Economics, Houghton Street, WC2A 2AE, England, United Kingdom. Electronic address: p.g.kanavos@lse.ac.uk.
Abstract
BACKGROUND: In this paper we discuss and present evidence on whether a generic Health Related Quality of Life (HRQoL) measurement tool, the EQ-5D-5L, captures the dimensions of quality of life (QoL) which patients consider significant. METHODS: An online survey, of individuals with a chronic condition, mainly breast cancer (BC), blood cancers (BLC), rheumatoid arthritis (RA), asthma, and rare diseases (RD) was conducted to collect data on HRQoL and important QoL aspects that respondents thought were not captured by the EQ-5D-5L. Patient organisations across 47 countries were invited to voluntarily share the survey tool with their membership network. RESULTS: 767 responses from 38 countries showed that important QoL aspects were not captured by EQ-5D-5L for 51% of respondents, including fatigue (19%) and medication side effects (12%), among others. Fatigue (17%) was also the most commonly reported QoL aspect that changed over the course of patients' illness, suggesting that the current version of the EQ-5D-5L might miss capturing significant clinical changes in important QoL domains. CONCLUSIONS: Utilisation of the EQ-5D-5L in HRQoL measurement raises inconsistencies in capturing QoL attributes and changes in disease-specific patient populations. Further research is needed to clarify the extent to which other generic HRQoL measurement tools capture the aspects of health that really matter for patients.
BACKGROUND: In this paper we discuss and present evidence on whether a generic Health Related Quality of Life (HRQoL) measurement tool, the EQ-5D-5L, captures the dimensions of quality of life (QoL) which patients consider significant. METHODS: An online survey, of individuals with a chronic condition, mainly breast cancer (BC), blood cancers (BLC), rheumatoid arthritis (RA), asthma, and rare diseases (RD) was conducted to collect data on HRQoL and important QoL aspects that respondents thought were not captured by the EQ-5D-5L. Patient organisations across 47 countries were invited to voluntarily share the survey tool with their membership network. RESULTS: 767 responses from 38 countries showed that important QoL aspects were not captured by EQ-5D-5L for 51% of respondents, including fatigue (19%) and medication side effects (12%), among others. Fatigue (17%) was also the most commonly reported QoL aspect that changed over the course of patients' illness, suggesting that the current version of the EQ-5D-5L might miss capturing significant clinical changes in important QoL domains. CONCLUSIONS: Utilisation of the EQ-5D-5L in HRQoL measurement raises inconsistencies in capturing QoL attributes and changes in disease-specific patient populations. Further research is needed to clarify the extent to which other generic HRQoL measurement tools capture the aspects of health that really matter for patients.
Authors: Suvi Sippola; Jussi Haijanen; Lauri Viinikainen; Juha Grönroos; Hannu Paajanen; Tero Rautio; Pia Nordström; Markku Aarnio; Tuomo Rantanen; Saija Hurme; Jukka-Pekka Mecklin; Juhani Sand; Airi Jartti; Paulina Salminen Journal: JAMA Surg Date: 2020-04-01 Impact factor: 14.766
Authors: A J L M Geraerds; Suzanne Polinder; Inge Spronk; Alfons G M Olde Loohuis; Annemieke de Groot; Madelon B Bronner; Juanita A Haagsma Journal: Qual Life Res Date: 2022-01-29 Impact factor: 4.147
Authors: Friederike-Marie Butscher; Stefan Rakete; Myriam Tobollik; Viola Mambrey; Dingani Moyo; Dennis Shoko; Shamiso Muteti-Fana; Nadine Steckling-Muschack; Stephan Bose-O'Reilly Journal: Health Qual Life Outcomes Date: 2020-08-18 Impact factor: 3.186